Active Ingredient(s): Lucinactant
FDA Approved: * March 6, 2012
Category: Respiratory Failure

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Surfaxin Overview

Lucinactant (trade name Surfaxin) is a liquid medication used to treat infant respiratory distress syndrome.[1] It is a pulmonary surfactant for infants who lack enough natural surfactant in their lungs. Whereas earlier medicines of the class, such as beractant (Survanta & Beraksurf), calfactant (Infasurf), and poractant (Curosurf), are derived from animals, lucinactant is synthetic. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA...

Read more Surfaxin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Surfaxin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Suspension: 5.8ml, 8.5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Surfaxin: (1 result)

Sorted by National Drug Code
  • 68628-500 Surfaxin Endotracheal Suspension by Discovery Laboratories, Inc.

Other drugs which contain Lucinactant or a similar ingredient: (1 result)